Search of the effect predictive factor in molecules target therapy for lung cancer
Project/Area Number |
24591156
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Niigata University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
WATANABE Satoshi 新潟大学, 医歯学総合病院, 特任助教 (50529740)
NAKATA Koh 新潟大学, 医歯学総合病院, 教授 (80207802)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | Lung cancer / EGFR-TKI / MDSCs / Predictive factor / Regulatory T細胞 / 制御性T細胞 / αGalCel |
Outline of Final Research Achievements |
Several immunologic parameters in patients with positive EGFR-mutation NSCLC during initial EGFR-TKI treatment were measured. The tendency that decreased frequency in the peripheral blood of the CD4+ CD25+ Foxp3+Regulatory T cell during tumor regression was found. In contrast, analysis of MDSCs or various humoral factors showed no particular tendency. During the series of experiments, we found that DDX3X expression and CD4+ CD25+ Foxp3+ Regulatory T cell affecting acquisition of resistancy to TKI.
|
Report
(4 results)
Research Products
(14 results)
-
-
-
-
[Journal Article] The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.2013
Author(s)
Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H.
-
Journal Title
Support Care Cancer
Volume: 21
Issue: 9
Pages: 2575-2581
DOI
Related Report
Peer Reviewed
-
[Journal Article] DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells2013
Author(s)
Koshio, J. Kagamu, H. Nozaki, K. Saida, Y. Tanaka, T. Shoji, S. Igarashi, N. Miura, S. Okajima, M. Watanabe, S. Yoshizawa, H. Narita, I.
-
Journal Title
Cancer Immunol Immunother
Volume: 62
Issue: 10
Pages: 1619-28
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia2012
Author(s)
Baba J, Watanabe S, Saida Y, Tanaka T, Miyabayashi T, Koshio J, Ichikawa K, Nozaki K, Koya T, Deguchi K, Tan C, Miura S, Tanaka H, Tanaka J, Kagamu H, Yoshizawa H, Nakata K, Narita I.
-
Journal Title
Blood
Volume: 12
Pages: 2417-2427
Related Report
Peer Reviewed
-
[Journal Article] Epitope diversification driven by non-tumor epitope-specific Th1 and Th17 mediates potent antitumor reactivity.2012
Author(s)
Ichikawa, K., Kagamu, H., Koyama, K., Miyabayashi, T., Koshio, J., Miura, S., Watanabe, S., Yoshizawa, H. and Narita, I.
-
Journal Title
Vaccine
Volume: 30
Issue: 43
Pages: 6190-7
DOI
Related Report
Peer Reviewed
-
[Journal Article] Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer : Quality of Life Analysis of North East Japan Study Group 002 Trial2012
Author(s)
Oizumi S, Kobayashi K, Inoue A, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Okinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T.
-
Journal Title
Oncologist
Volume: 17
Issue: 6
Pages: 863-70
DOI
Related Report
Peer Reviewed
-
-
-
-